Sandoz Group AG (SWX:SDZ)
37.50
+0.24 (0.64%)
May 9, 2025, 1:45 PM CET
Sandoz Group AG Revenue
In the year 2024, Sandoz Group AG had annual revenue of $10.38B USD with 4.06% growth. Sandoz Group AG had revenue of $5.32B in the half year ending December 31, 2024, with 14.92% growth.
Revenue
$10.38B
Revenue Growth
+4.06%
P/S Ratio
1.71
Revenue / Employee
$470.95K
Employees
22,049
Market Cap
16.05B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.38B | 405.00M | 4.06% |
Dec 31, 2023 | 9.98B | 673.00M | 7.23% |
Dec 31, 2022 | 9.31B | -372.00M | -3.84% |
Dec 31, 2021 | 9.68B | 20.00M | 0.21% |
Dec 31, 2020 | 9.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Novartis AG | 47.05B |
Lonza Group AG | 6.57B |
Alcon | 8.98B |
Galderma Group AG | 4.02B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.71B |
Ypsomed Holding AG | 617.07M |
Sandoz Group AG News
- 6 days ago - Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Sandoz inks agreement with Shanghai Henlius for Bristol Yervoy biosimilar - Seeking Alpha
- 24 days ago - Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug - Benzinga
- 25 days ago - Amgen faces antitrust lawsuit from Sandoz over Enbrel patents - Seeking Alpha
- 25 days ago - Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ... - GuruFocus
- 4 weeks ago - Novartis After Sandoz: The Business Without Generics - Seeking Alpha
- 4 weeks ago - Competencia investiga a Sandoz, Alliance Healthcare España y Bluetab Solutions - elEconomista.es
- 5 weeks ago - Sandoz: Upgrading To A Buy On 2028 Expectations - Seeking Alpha